The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The MAPK pathway across different malignancies: A new perspective
Open accessAbstract
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway is activated by upstream genomic events and/or activation of multiple signaling events in which information coalesces at this important nodal pathway point. This pathway is tightly regulated under normal conditions by phosphatases and bidirectional communication with other pathways, like the protein kinase B/mammalian target of rapamycin (AKT/m‐TOR) pathway. Recent evidence indicates that the MAPK/ERK signaling node can function as a tumor suppressor as well as the more common pro‐oncogenic signal. The effect that predominates depends on the intensity of the signal and the context or tissue in which the signal is aberrantly activated. Genomic profiling of tumors has revealed common mutations in MAPK/ERK pathway components, such as v‐raf murine sarcoma viral oncogene homolog B1 (BRAF). Currently approved for the treatment of melanoma, inhibitors of BRAF kinase are being studied alone and in combination with inhibitors of the MAPK and other pathways to optimize the treatment of many tumor types. Therapies targeted toward MAPK/ERK components have various response rates when used in different solid tumors, such as colorectal cancer and ovarian cancer. Understanding the differential nature of activation of the MAPK/ERK pathway in each tumor type is critical in developing single and combination regimens, because different tumors have unique mechanisms of primary and secondary signaling and subsequent sensitivity to drugs. Cancer 2014;120:3446–3456. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Involvement of the Activation Loop of ERK in the Detachment from Cytosolic Anchoring
Wolf, I., Rubinfeld, H., Yoon, S., Marmor, G., Hanoch, T., & Seger, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103352200 · Cited by 84
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“Senescence involves the inhibition of cell proliferation through terminal cell cycle arrest.(29) Abnormal activation of MAPK/ ERK by RAS causes degradation of proteins required for both migration and progression through the cell cycle, as demonstrated in a model of normal fibroblasts and validated in benign prostate t…”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Cited by
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Biomarkers, oxidative stress and autophagy in skin aging
Gu, Y., Han, J., Jiang, C., & Zhang, Y. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101036 · Cited by 762
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 569
Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
Yan, X., Qi, M., Li, P., Zhan, Y., & Shao, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0179-x · Cited by 545
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Sugiura, R., Satoh, R., & Takasaki, T. (2021) · Cells · doi:10.3390/cells10102509 · Cited by 369
Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
Van Weelden, G., Bobiński, M., Okła, K., Van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 330
Targeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
Jackson, M., Marks, L., May, G. H. W., & Wilson, J. B. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170053 · Cited by 295
Role of Phytochemicals in Cancer Chemoprevention: Insights
George, B. P., Chandran, R., & Abrahamse, H. (2021) · Antioxidants · doi:10.3390/antiox10091455 · Cited by 295
Lau, T.-S., Chan, L. K.-Y., Wong, E. C.-H., Hui, C. W.-C., Sneddon, K., Cheung, T.-H., Yim, S.-F., Lee, J. H.-S., Yeung, C. S.-Y., Chung, T. K.-H., et al. (2017) · Oncogene · doi:10.1038/onc.2016.509 · Cited by 88
Self-citationClinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma
Kenchappa, R. S., Radnai, L., Young, E. J., Zarco, N., Lin, L., Dovas, A., Meyer, C. T., Haddock, A., Hall, A., Toth, K., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.019 · Cited by 21
Redefining Colorectal Cancer by Tumor Biology
Salem, M. E., Puccini, A., & Tie, J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279867 · Cited by 14
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14
Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG
Huang, S.-C., Adhikari, S., Afroze, R., Brewer, K., Calderwood, E. F., Chouitar, J., England, D. B., Fisher, C., Galvin, K. M., Gaulin, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.049 · Cited by 10
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
Sun, K., Jin, L., Karolová, J., Vorwerk, J., Hailfinger, S., Opalka, B., Zapukhlyak, M., Lenz, G., & Khandanpour, C. (2023) · Cancers · doi:10.3390/cancers15082373 · Cited by 9
Antiprolactinoma Effect of Hordenine by Inhibiting MAPK Signaling Pathway Activation in Rats
Wang, X., Guo, R.-Z., Ma, L., Ding, Q.-Y., Meng, J.-H., Chen, Y.-G., & Wu, J.-H. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/3107290 · Cited by 6
“More, the complex signaling cascades of MAPK were involved in tumorigenesis, development, and drug resistance [11].”
Background
Metadata
- Authors
- Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-06-19
- Volume
- 120
- Issue
- 22
- Pages
- 3446-3456
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1490956705
- Cited by
- 956
- References
- 100
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.